Twist Bioscience 10-Kyear ended 2026-09-30

Positive

AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.

Filed 2026-11-16 16:17 ET

Key figures · FY2026 · period ended 2026-09-30

  • Revenue
    Revenue history
    Q1 FY2025$88.7M
    Q2 FY2025$92.8M
    Q3 FY2025$96.1M
    Q4 FY2025$99.0MQ4: year minus nine months
    Q1 FY2026$103.7M
    Q2 FY2026$110.7M
    Q3 FY2026$118.4M
    Q4 FY2026$126.6MQ4: year minus nine months

    Quarters; the tile shows the full year.

    $459.4MYoY +22.0%
  • Operating income
    Operating income history
    Q1 FY2025−$34.6M
    Q2 FY2025−$41.6M
    Q3 FY2025−$30.1M
    Q4 FY2025−$29.9MQ4: year minus nine months
    Q1 FY2026−$32.9M
    Q2 FY2026−$45.9M
    Q3 FY2026−$36.3M
    Q4 FY2026−$24.4MQ4: year minus nine months

    Quarters; the tile shows the full year.

    −$139.5MYoY −2.3%
  • Net income
    Net income history
    Q1 FY2025−$31.6M
    Q2 FY2025−$39.3M
    Q3 FY2025$20.4M
    Q4 FY2025−$27.1MQ4: year minus nine months
    Q1 FY2026−$30.5M
    Q2 FY2026−$44.0M
    Q3 FY2026−$35.1M
    Q4 FY2026−$20.6MQ4: year minus nine months

    Quarters; the tile shows the full year.

    −$130.2MYoY −67.6%
  • Total assets
    Total assets history
    Q1 FY2025$608.6M
    Q2 FY2025$595.6M
    Q3 FY2025$643.6M
    Q4 FY2025$641.9M
    Q1 FY2026$638.1M
    Q2 FY2026$676.2M
    Q3 FY2026$672.4M
    Q4 FY2026$1.1B
    $1.1BYoY +74.8%
  • Total debt
    Total debt history
    Q1 FY2025$15.0M
    Q2 FY2025$15.0M
    Q3 FY2025$15.0M
    Q4 FY2025$15.0M
    Q1 FY2026$15.0M
    Q2 FY2026$15.0M
    Q3 FY2026$15.0M
    Q4 FY2026$15.0M
    $15.0MYoY 0.0%
  • Shareholders' equity
    Shareholders' equity history
    Q1 FY2025$455.9M
    Q2 FY2025$440.1M
    Q3 FY2025$478.2M
    Q4 FY2025$473.0M
    Q1 FY2026$456.1M
    Q2 FY2026$455.1M
    Q3 FY2026$445.7M
    Q4 FY2026$888.0M
    $888.0MYoY +87.8%
  • Tangible book value
    Tangible book value history
    Q1 FY2025$355.9Mderived from year-to-date
    Q2 FY2025$340.3Mderived from year-to-date
    Q3 FY2025$382.3Mderived from year-to-date
    Q4 FY2025$377.3MQ4: year minus nine months
    Q1 FY2026$360.7Mderived from year-to-date
    Q2 FY2026$359.9Mderived from year-to-date
    Q3 FY2026$350.8Mderived from year-to-date
    Q4 FY2026$771.7MQ4: year minus nine months
    $771.7MYoY +104.5%
Notes on other figures in this summary (3)
  • Capital expenditures (fiscal year): Summary: $47.6M · Filing: $54.5M

    Comment from AI: The summary's $47.6M is purchases of property and equipment; FY2026 capital expenditures of $54.5M also include $6.95M of intangible-asset purchases.

  • Free cash flow (fiscal year): Summary: $(89.0)M · Filing: −$96.0M

    Comment from AI: The summary's $(89.0)M deducts only property and equipment purchases; free cash flow of $(96.0)M also deducts intangible-asset purchases.

  • Cash and cash equivalents: Summary: $582M · Filing: $534.0M

    Comment from AI: The summary's $582M includes short-term investments; cash and cash equivalents of $534.0M exclude them.

How this filing reads

Each score is our read of the filing's tone, not a rating. The bar runs from −1 (bad) to +1 (good). The tick marks the typical filing on Goblin, and the shaded band is where the middle half of filings score.How we read filings

  • HealthCash and investments were $582M against $89M free-cash-flow use and $63.3M of commitments.
  • MomentumRevenue grew 22% and gross margin rose 170 bp, while operating loss widened to $139M.
  • OutlookManagement expects FY2027 growth, while the $150M expansion precedes secured demand.

Executive Summary

Twist Bioscience sells synthetic DNA, sequencing-preparation tools and antibody-discovery services to diagnostics developers, drugmakers, researchers and supply partners. It is expanding from a DNA supplier into a protein-building and data partner for AI-enabled drug discovery, while serving growing commercial diagnostics customers. FY2026 revenue rose 22%, with drug-discovery services outpacing product sales, but commercial expansion and litigation costs prevented higher gross profit from narrowing the operating loss. Equity financing strengthened liquidity ahead of manufacturing expansion; investors must judge whether these investments turn emerging customer demand into durable growth and lower cash consumption.

What's Happening in the Business

AI-enabled drug discovery is changing Twist’s customer relationships. Customers computationally design antibodies and proteins, then use Twist to build, test and characterize them. Twist combined synthetic biology and antibody-discovery offerings into DNA Synthesis and Protein Solutions to reflect their increasing joint use. Management expects further AI-related growth in FY2027, although orders have little long-term contractual protection.

The February Invenra agreement broadens this offering through a co-exclusive license to its B-Body bispecific-antibody platform and a minority investment. Total consideration was $33.8M, largely paid in shares. Following the prior-year DNA data-storage spinout to AtlasBase, Twist is concentrating resources on its core synthesis, protein and sequencing businesses.

NGS Applications, its sequencing sample-preparation business, is becoming more exposed to large commercial diagnostics customers. Liquid biopsy and testing for residual cancer offer recurring volume opportunities, but Twist’s growth increasingly depends on customers’ commercialization, reimbursement and decisions about outsourcing.

Twist plans ≈$150M of capital expenditure over the next two fiscal years at existing facilities, intended to support more than $1.0B of annual revenue—not a revenue forecast. Expanding capacity and automation could improve unit costs, but requires spending before demand is secured.

Key Financial Highlights

FY2026 ended 9/30/2026; comparisons are with FY2025.

Metric FY2026 Change / FY2025 Investor interpretation
Revenue $459M +22% Growth accelerated from 20% in FY2025, led by therapeutics demand.
Gross margin 52.4% +170 bp Greater volume spread relatively fixed manufacturing costs across more sales.
Operating loss $(139)M $(136)M Commercial staffing, outside services and litigation absorbed gross-profit gains.
Net loss $(130)M $(77.7)M FY2025 benefited from a nonrecurring $48.8M data-storage disposal gain.
Free cash flow $(89.0)M $(75.6)M Higher equipment investment outweighed improved operating cash flow.
Cash, cash equivalents and short-term investments $582M $232M Equity issuance, rather than operating cash generation, rebuilt liquidity.
Product category FY2026 revenue Y/Y change
DNA Synthesis and Protein Solutions $222M +32%
NGS Applications $238M +14%
  • Growth drivers: Therapeutics revenue reached $162M, +47%, contributing most of the company’s revenue increase. Revenue recognized over time, primarily antibody-discovery services, reached $58.7M, +122%, versus 14% growth in primarily product revenue. Diagnostics revenue reached $164M, +13%, supporting sequencing demand.
  • Volume versus pricing: Genes shipped rose 43% to ≈1.34M, while customers increased 8% to 4,100. Lower-priced offerings lifted units but reduced average prices; gene complexity and length also prevent shipments from translating proportionately into revenue.
  • Operating costs: Selling, general and administrative expense reached $301M, +22%, including $28.5M more personnel costs, primarily commercial additions. R&D fell 11% to $71.8M following the data-storage sale, while net litigation settlement costs added $7.21M.
  • Cash versus earnings: Operating cash use was $41.4M versus $47.6M, substantially below the current-year net loss because expenses included $69.9M of stock-based compensation and $26.5M of depreciation and amortization. Equipment purchases increased to $47.6M from $28.0M; free cash flow here deducts those purchases from operating cash flow.
  • Funding and dilution: Public-offering and at-the-market sales generated $425M net. Shares outstanding increased 12% to 67.8M, including financing and other issuance. Management expects existing liquidity to cover planned needs for at least 12 months from filing.
  • Future commitments: Capital commitments and leases not yet commenced total ≈$63.3M, exceeding annual operating cash use; $18.4M of capital commitments is substantially due within 12 months, with ≈$44.9M of rent extending through 2037 and payments beginning in FY2028. Remaining performance obligations were $21.6M, including $15.9M expected within 12 months, but exclude substantially all short-duration product orders and are future revenue—not cash.

Risk Assessment

  • Customer dependence: AI-discovery growth is concentrated among relatively few customers without firm long-term purchasing commitments, while diagnostics growth depends on customers’ funding, reimbursement and commercialization.
  • Capacity and funding: Planned manufacturing expansion precedes secured demand; underutilization could weaken margins and prolong cash burn, potentially requiring further dilutive financing.
  • Production continuity: Manufacturing is concentrated in Wilsonville and South San Francisco, and a critical synthesis component has one supplier; disruption or lengthy substitute qualification could interrupt deliveries.
  • Biosecurity and diagnostic regulation: Changes to nucleic-acid screening requirements or authorities treating research-use products as clinical diagnostics could restrict orders, slow delivery or increase compliance costs.

What to Watch

  • AI-discovery durability: Management expects further FY2027 growth. Sustained synthesis and protein revenue growth with broader customer participation would support the opportunity; cancellations or insourcing would undermine it.
  • Diagnostics scaling: Diagnostics revenue is $164M and sequencing demand increasingly comes from large commercial customers. Continued ordering as their tests commercialize would validate the opportunity; reimbursement setbacks or internal sample preparation would weaken it.
  • Manufacturing returns: The planned capacity expansion succeeds if revenue growth and gross-margin improvement accompany investment; rising capacity without sufficient orders would indicate underutilization.
  • Path to self-funding: Operating losses barely improved despite sales growth. Later filings should show gross-profit gains outpacing commercial spending and lower cash consumption; persistent losses and further issuance would weaken shareholder returns.

Longer version: the summary of each of the report's 7 sections, written by an AI model from the same filing.

Changes since the previous 10-Q

Since the Q3 FY2026 10-Q:

The core bet (strengthened): Scalable DNA synthesis and broader antibody discovery serve therapeutics, diagnostics and research customers. → AI customers increasingly combine synthesis and antibody discovery; therapeutics demand continues expanding.

  1. Watch item improved Operating leverage
    Q3 operating loss was $36.3M on $118M revenue; spending moderation was planned. → Q4 operating loss narrowed to approximately $24M as revenue rose to $126.6M.
  2. Risk materialized Equity dilution
    The $200M equity program was unused; continued cash consumption threatened shareholder dilution. → Equity sales raised $425M, including approximately $97M through the previously unused program.

Was this summary useful?

Figures are computed from the filing's XBRL data; the summary and scores are written by an AI model reading the filing.

Model 006 · prompt v229 · 2026-11-17 15:44:00Z

Feedback